Biotechnology
Biopharmaceutical
Pharmaceutical
TG Therapeutics
$6.889876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$6.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.56 (-7.58%) Today
+$0.05 (0.73%) After Hours
Why Robinhood?
You can buy or sell TGTX and other stocks, options, ETFs, and crypto commission-free!
About
TG Therapeutics, Inc. Common Stock, also called TG Therapeutics, is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Read More Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
Employees
105
Headquarters
New York, New York
Founded
1993
Market Cap
619.80M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.45M
High Today
$7.45
Low Today
$6.82
Open Price
$7.37
Volume
931.38K
52 Week High
$16.00
52 Week Low
$3.32
Collections
Biotechnology
Biopharmaceutical
Pharmaceutical
Health
Therapy
Technology
News
Yahoo FinanceMar 11
What Makes TG Therapeutics (TGTX) a New Strong Buy Stock
TG Therapeutics (TGTX) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Price Paid on Robinhood
3% Lower
Right Now
52 Week Low
$3.32
Average Price Paid
$7.08
52 Week High
$16.00
Earnings
-$0.59
-$0.53
-$0.48
-$0.42
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.42 per share
Actual
Expected Mar 29, Pre-Market